Corporate Compliance Officer

Capricor Therapeutics·
San Diego, CA
3w ago
Full-timeCapricor Therapeutics
$210K - $270K/yr(from employer)

Description

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002), our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX™ exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most. The Corporate Compliance Officer is responsible for leading, developing, and overseeing the company’s comprehensive corporate compliance program, with a primary focus on internal compliance, trade compliance, reporting requirements, document retention, quality compliance, anti-corruption, data privacy and industry standards in the pharmaceutical/biotech sector. Reporting to the Executive Vice President-General Counsel, this role partners closely with Commercial, Clinical, CMC, Quality, Regulatory, and Operations to ensure all company activities align with applicable laws, regulations, contractual obligations, and ethical standards. The ideal candidate is a seasoned compliance professional with deep pharmaceutical or biotech experience, proven leadership in building and managing compliance programs, with experience in international trade compliance involving Europe and/or Japan (e.g., export controls, sanctions, trade regulations, customs, or cross-border technology transfer).
Capricor Therapeutics

Capricor Therapeutics

BIOTECHNOLOGY

Cell and exosome-based therapies for rare diseases

LocationSAN DIEGO, CA
Open Jobs35
Rare Diseases
View Company Profile

Pipeline

CAP-1002 Allogeneic Cardiosphere-Derived CellsN/A
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of FamiliesN/A
Allogeneic Cardiosphere-Derived CellsPhase 1
CAP-1002 Allogeneic Cardiosphere-Derived CellsPhase 1/2
CenderitidePhase 1/2